| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C19H23NO4 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
HA-CD44 interaction inhibitor 2 is a CD44 inhibitor that can block the interaction between hyaluronic acid (HA) and CD44. It acts as an antiproliferative agent against CD44+ cancer cells, and can disrupt the integrity of cancer spheres and reduce cancer cell viability in a dose-dependent manner. It has been used in tumor research[1]. It is supplied as a white to off-white solid (C19H23NO4, MW 329.39) at 99.36% purity.
Physical & Chemical Properties
| CAS Number | 3009761-01-4 |
|---|---|
| Molecular Formula | C19H23NO4 |
| Molecular Weight | 329.39 g/mol |
| Purity | 99.36% |
| Appearance | Solid |
| Color | White to off-white |
| SMILES | OC1=CC=CC2=C1CCN(CC3=CC(OC)=C(OC)C(OC)=C3)C2 |
| Signaling Pathway | Immunology/Inflammation |
| Solubility | In Vitro: DMSO: 100 mg/mL (303.59 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (303.59 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | 2.5 mg/mL (7.59 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 2.5 mg/mL. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | 2.5 mg/mL (7.59 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 2.5 mg/mL. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | 2.5 mg/mL (7.59 mM); clear solution; requires sonication |
| How to prepare | Gives a clear solution at 2.5 mg/mL. Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
HA-CD44 interaction inhibitor 2 potently inhibits MDA-MB-231 cell proliferation at 0.01-100 μM over 5 days (EC50 = 0.59 μM)[1]. Treatment at 120 μg/mL for 30 min blocks HA-CD44 binding in MDA-MB-231 cells[1]. At 1-100 μM for 5 days, the compound disrupts the integrity of MDA-MB-231 3D spheroids and lowers their viability in a dose-dependent manner[1].
Cell Viability Assay[1]
| Cell Line | MDA-MB-231 human breast carcinoma cells |
|---|---|
| Concentration | 1, 10 and 100 μM |
| Incubation Time | 5 days |
| Result | Reduced viability in a dose-dependent manner. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Hyaluronan regulates the assembly structure and biofunction of polycationic silk fibroin to boost microfracture. Bioact Mater 2025 Nov 28:57:754-767. PMID: 41403565
Effectiveness and mechanism of different molecular weight hyaluronic acid in repairing intestinal barrier function. Int J Biochem Cell Biol 2026 Apr 27:106962. PMID: 42055395
Res Sq. 2026 May 6.
